DD128332A5 - Verfahren zur herstellung von verbindungen mit antidepressiver wirkung - Google Patents

Verfahren zur herstellung von verbindungen mit antidepressiver wirkung

Info

Publication number
DD128332A5
DD128332A5 DD7600191893A DD19189376A DD128332A5 DD 128332 A5 DD128332 A5 DD 128332A5 DD 7600191893 A DD7600191893 A DD 7600191893A DD 19189376 A DD19189376 A DD 19189376A DD 128332 A5 DD128332 A5 DD 128332A5
Authority
DD
German Democratic Republic
Prior art keywords
preparing compounds
antidepressive effect
antidepressive
effect
preparing
Prior art date
Application number
DD7600191893A
Other languages
German (de)
English (en)
Inventor
Hendricus B A Welle
Volkert Claassen
Original Assignee
Philips Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philips Nv filed Critical Philips Nv
Publication of DD128332A5 publication Critical patent/DD128332A5/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DD7600191893A 1975-03-20 1976-03-17 Verfahren zur herstellung von verbindungen mit antidepressiver wirkung DD128332A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (1)

Publication Number Publication Date
DD128332A5 true DD128332A5 (de) 1977-11-09

Family

ID=19823424

Family Applications (1)

Application Number Title Priority Date Filing Date
DD7600191893A DD128332A5 (de) 1975-03-20 1976-03-17 Verfahren zur herstellung von verbindungen mit antidepressiver wirkung

Country Status (27)

Country Link
US (1) US4085225A (ja)
JP (1) JPS6026776B2 (ja)
AR (2) AR211011A1 (ja)
AT (1) AT340895B (ja)
AU (1) AU505358B2 (ja)
BE (1) BE839744A (ja)
CA (1) CA1076142A (ja)
CH (4) CH626057A5 (ja)
DD (1) DD128332A5 (ja)
DE (1) DE2610886A1 (ja)
DK (1) DK144942C (ja)
ES (1) ES446192A1 (ja)
FI (1) FI61875C (ja)
FR (1) FR2304336A1 (ja)
GB (1) GB1535226A (ja)
GR (1) GR60052B (ja)
HU (1) HU171030B (ja)
IE (1) IE43768B1 (ja)
IL (1) IL49238A (ja)
IT (1) IT1063064B (ja)
MX (1) MX9203723A (ja)
NL (1) NL7503310A (ja)
PL (3) PL101951B1 (ja)
SE (1) SE410312B (ja)
SU (3) SU635867A3 (ja)
YU (1) YU39345B (ja)
ZA (1) ZA761434B (ja)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
ES2145977T3 (es) * 1995-08-16 2000-07-16 Lilly Co Eli Potenciacion de la respuesta de la serotonina.
IN182588B (ja) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (ja) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
AU2001255654B2 (en) 2000-04-24 2005-09-22 Aryx Therapeutics Materials and methods for the treatment of depression
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
ES2666188T3 (es) * 2001-10-12 2018-05-03 Azevan Pharmaceuticals, Inc. Antagonistas del v1a de vasopresina beta-lactámicos
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
EP1691811B1 (en) 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1868434A4 (en) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
AR056980A1 (es) 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
WO2006116151A1 (en) 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
TW200716583A (en) * 2005-04-22 2007-05-01 Wyeth Corp Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
CA2614289A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
KR101523776B1 (ko) 2005-07-19 2015-05-28 아제반 파마슈티칼스, 인코퍼레이티드 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
DK2491038T3 (da) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
PL2587919T3 (pl) 2010-07-01 2018-05-30 Azevan Pharmaceuticals, Inc. Sposoby leczenia zespołu stresu pourazowego
EP2685966A1 (en) 2011-03-17 2014-01-22 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
PT2981518T (pt) * 2013-04-03 2021-06-04 Zcl Chemicals Ltd Um processo melhorado para a preparação de maleato de fluvoxamina
JP6723930B2 (ja) 2014-02-07 2020-07-15 エムティーエー タモガトット クタトクソポルトク イロダジャ シグマ−１−受容体アゴニスト化合物の新規使用
NZ724718A (en) 2014-03-28 2023-04-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
CA3016706A1 (en) * 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
ES2926179T3 (es) 2016-11-24 2022-10-24 Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag Utilización de composiciones para la conservación de órganos/tejidos
CA3075759A1 (en) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
ES446192A1 (es) 1977-10-01
ZA761434B (en) 1977-10-26
MX9203723A (es) 1992-07-01
IL49238A (en) 1978-08-31
PL101951B1 (pl) 1979-02-28
CH629761A5 (de) 1982-05-14
AU505358B2 (en) 1979-11-15
DK144942B (da) 1982-07-12
US4085225A (en) 1978-04-18
JPS6026776B2 (ja) 1985-06-25
BE839744A (fr) 1976-09-20
FI760699A (ja) 1976-09-21
CH629184A5 (de) 1982-04-15
ATA195476A (de) 1977-05-15
HU171030B (hu) 1977-10-28
CH629477A5 (de) 1982-04-30
DE2610886C2 (ja) 1987-09-24
DK115976A (da) 1976-09-21
IE43768B1 (en) 1981-05-20
IL49238A0 (en) 1976-05-31
AT340895B (de) 1978-01-10
FR2304336B1 (ja) 1979-09-28
DE2610886A1 (de) 1976-10-07
YU71476A (en) 1982-10-31
FI61875C (fi) 1982-10-11
AR211011A1 (es) 1977-10-14
FR2304336A1 (fr) 1976-10-15
IE43768L (en) 1976-09-20
PL100614B1 (pl) 1978-10-31
SU620206A3 (ru) 1978-08-15
SU635867A3 (ru) 1978-11-30
JPS51125345A (en) 1976-11-01
SU645559A3 (ru) 1979-01-30
GB1535226A (en) 1978-12-13
GR60052B (en) 1978-04-04
DK144942C (da) 1982-12-06
AR211153A1 (es) 1977-10-31
SE7603341L (sv) 1976-09-21
CA1076142A (en) 1980-04-22
CH626057A5 (ja) 1981-10-30
PL100052B1 (pl) 1978-08-31
YU39345B (en) 1984-10-31
IT1063064B (it) 1985-02-11
SE410312B (sv) 1979-10-08
AU1214776A (en) 1977-09-22
FI61875B (fi) 1982-06-30
NL7503310A (nl) 1976-09-22

Similar Documents

Publication Publication Date Title
DD128332A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
DD130857A5 (de) Verfahren zur herstellung von n-phosphonomethylglycintriestern
DD131931A5 (de) Verfahren zur herstellung von spiro-hydantoin-verbindungen
DD129330A5 (de) Verfahren zur herstellung von antitumorsubstanzen
DD131649A5 (de) Verfahren zur herstellung von n-(perfluoracyl)-n-phosphono-methyl-glycin-verbindungen
DD127928A5 (de) Verfahren zur herstellung heterocyclischer verbindungen
DD131858A5 (de) Verfahren zur herstellung von 3-chlorcephemverbindungen
DD130036A5 (de) Verfahren zur herstellung von optisch aktiven 11-desoxy-16-aryloxy-omega-tetranorprostaglandinen
AT341668B (de) Verfahren zur herstellung von 7-aminocephemverbindungen
DD129326A5 (de) Verfahren zur herstellung von 1,4-diphenyl-3-pyrazolin-5-onen
AT333305B (de) Verfahren zur herstellung von phosphonothioureidoverbindungen
DD128330A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
DD131562A5 (de) Verfahren zur herstellung von 5-pregnen-derivaten
AT342191B (de) Verfahren zur herstellung von arzneimittelkombinationen
DD122961A5 (de) Verfahren zur herstellung von diphenylaether-derivaten
AT352914B (de) Verfahren zur herstellung von polyen- verbindungen
DD128329A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
DD122976A5 (de) Verfahren zur herstellung von pyridoepoxyaethanen
DD122964A5 (de) Verfahren zur herstellung von prostensaeurederivaten
AT339268B (de) Verfahren zur herstellung von acetoxybutanolen
DD133327A5 (de) Verfahren zur herstellung von organischen verbindungen
AT350199B (de) Verfahren zur herstellung von 17-monoestern von 17alfa,21-dihydroxysteroiden
DD133147A5 (de) Verfahren zur herstellung antihelmintischer verbindungen
AT338775B (de) Verfahren zur herstellung von 4-oxa-5-hydroxypolycycloalken-3-onen
DD128709A5 (de) Verfahren zur herstellung von dekahydrochinolinderivaten